Pharming Group (NASDAQ:PHAR) Hits New 12-Month High - Should You Buy?

Key Points

• Pharming Group's shares hit a new 52-week high of $12.73, reflecting increased trading interest as the stock is up 1.6% from its previous close.
• The company reported a quarterly earnings per share (EPS) of $0.06, exceeding estimates, with revenue of $93.20 million compared to expectations of $70.36 million.
• Institutional investor Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group by 8.6%, showcasing growing confidence in the company’s performance.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $12.73 and last traded at $12.68, with a volume of 10837 shares. The stock had previously closed at $12.48.

Pharming Group Stock Performance

The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07. The stock has a fifty day simple moving average of $10.84 and a two-hundred day simple moving average of $9.54. The firm has a market capitalization of $825.95 million, a P/E ratio of -92.74 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.16. The company had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. On average, research analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,147 shares of the company's stock after buying an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.